Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel

Infection. 2022 Apr;50(2):439-446. doi: 10.1007/s15010-021-01703-9. Epub 2021 Sep 25.

Abstract

Background: The long-term course of immunity among individuals with a history of COVID-19, in particular among those who received a booster vaccination, has not been well defined so far.

Methods: SARS-CoV-2-specific antibody levels were measured by ELISA over 1 year among 136 health care workers infected during the first COVID-19 wave and in a subgroup after booster vaccination approximately 1 year later. Furthermore, spike-protein-reactive memory T cells were quantified approximately 7 months after the infection and after booster vaccination. Thirty healthy individuals without history of COVID-19 who were routinely vaccinated served as controls.

Results: Levels of SARS-CoV-2-specific IgM- and IgA-antibodies showed a rapid decay over time, whereas IgG-antibody levels decreased more slowly. Among individuals with history of COVID-19, booster vaccination induced very high IgG- and to a lesser degree IgA-antibodies. Antibody levels were significantly higher after booster vaccination than after recovery from COVID-19. After vaccination with a two-dose schedule, healthy control subjects developed similar antibody levels as compared to individuals with history of COVID-19 and booster vaccination. SARS-CoV-2-specific memory T cell counts did not correlate with antibody levels. None of the study participants suffered from a reinfection.

Conclusions: Booster vaccination induces high antibody levels in individuals with a history of COVID-19 that exceeds by far levels observed after recovery. SARS-CoV-2-specific antibody levels of similar magnitude were achieved in healthy, COVID-19-naïve individuals after routine two-dose vaccination.

Keywords: Antibody-mediated immunity; COVID-19; Cellular immunity; SARS-CoV-2; SARS-CoV-2-vaccination.

MeSH terms

  • Antibodies, Viral
  • COVID-19* / prevention & control
  • Follow-Up Studies
  • Humans
  • SARS-CoV-2
  • Vaccination

Substances

  • Antibodies, Viral